| Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study 2020 · berberine group · Adults aged 18–75 with one to six histologically confirmed colorectal adenomas removed by polypectomy | 600 mg | 2 years | 553 |
| A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment 2020 · berberine and amoxycillin (BA)-based quadruple therapy group · Adults aged 18–70 years, either sex, with H. pylori infection whose eradication treatment had previously failed at least once | 900 mg | 2 weeks | 329 |
| Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori 2022 · berberine triple scheme (observation group) · Adults aged 18–70 with initial Helicobacter pylori infection and dyspepsia, who had not previously received eradication therapy | 900 mg | 2 weeks | 262 |
| Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial 2023 · A group (berberine triple therapy) · Adults aged 18–70 years, both sexes, with untreated initial Helicobacter pylori infection and dyspepsia symptoms | 1 g | 2 weeks | 100 |
| Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion 2013 · Berberine group · Patients with metabolic syndrome; age and sex distribution not reported | 1.5 g | 90 days | 12 |
| Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial 2022 · berberine · People with schizophrenia spectrum disorders and antipsychotic-associated weight gain who had developed metabolic syndrome | 600 mg | 12 weeks | 58 |
| Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia 2022 · berberine group · Patients with schizophrenia receiving adjunctive atypical antipsychotic treatment | 900 mg | 8 weeks | 32 |
| Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin 2022 · berberine group · Patients with schizophrenia on a stable dose of a single antipsychotic for at least one month | 900 mg | 8 weeks | 27 |
| Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy 2010 · Berberine trial group · Patients with cervical cancer receiving pelvic radiotherapy; age and sex not reported | 900 mg | — | 21 |
| Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy 2010 · Berberine oral group · Patients with seminoma or lymphoma receiving abdominal radiotherapy; age and sex not reported | 900 mg | — | 18 |
| Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy 2010 · Berberine treatment for patients with radiation-induced acute intestinal symptoms · Patients with radiation-induced acute intestinal symptoms receiving abdominal or pelvic radiotherapy; age and sex not reported | 900 mg | 3 weeks | 8 |
| Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial 2017 · berberine-containing quadruple therapy · Adults aged 18–70 with documented Helicobacter pylori infection and upper gastrointestinal symptoms | 200 mg | 2 weeks | 304 |
| A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome 2015 · berberine group · Patients with diarrhea-predominant irritable bowel syndrome (IBS-D); age and sex not reported | 400 mg | 8 weeks | — |
| Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial 2025 · 500-mg group · Adults aged 41-76 with type 2 diabetes | 1 g | 12 weeks | 37 |
| Efficacy of berberine in patients with type 2 diabetes mellitus 2008 · Berberine group, study B (combination therapy) · Adults with type 2 diabetes inadequately controlled on diet and existing antidiabetic therapy | 1.5 g | 13 weeks | 48 |
| Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial 2025 · 1000-mg group · Adults aged 41-76 with type 2 diabetes | 2 g | 12 weeks | 38 |
| Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation 2018 · combined lipid-lowering nutraceutical (Armolipid Plus®) · Adults with hypertriglyceridemia and residual dyslipidemia, already tolerating micronized fenofibrate; ages and sex not reported | 500 mg | 8 weeks | 20 |
| Efficacy of berberine in patients with type 2 diabetes mellitus 2008 · Berberine group, study A (monotherapy) · Adults aged 25–75 with newly diagnosed type 2 diabetes | 1.5 g | 13 weeks | 18 |
| Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans 2022 · Berberine powder · Healthy men and women | 800 mg | 1 day | 12 |
| Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention 2012 · berberine-treated group · Adults with acute coronary syndrome undergoing percutaneous coronary intervention; age and sex not specified | 900 mg | 30 days | 61 |
| [Effects of berberine on serum inflammatory factors and carotid atherosclerotic plaques in patients with acute cerebral ischemic stroke] 2016 · berberine group · Patients with acute cerebral ischemic stroke | 900 mg | 90 days | 60 |
| Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study 2005 · BBR-treated group · Renal-transplant recipients receiving cyclosporin A | 600 mg | 90 days | 52 |
| [Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia] 2016 · berberine group (the treatment group) · Patients with mild hyperlipidemia; ages and sex not reported | 900 mg | 26 weeks | 49 |
| Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study 2021 · Be group (berberine) · Adults aged 18–70 with newly diagnosed hyperglycemia | 1 g | 16 weeks | 49 |
| Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial 2021 · berberine group · Chinese men aged 20–65 with hyperlipidemia and no history of chronic diseases | 1 g | 12 weeks | 42 |
| Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients 2022 · observation group · Patients with Parkinson's disease; age and sex not specified | 600 mg | 90 days | 34 |
| Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways 2019 · BBR group · Adults with acute coronary syndrome who had undergone primary or elective PCI; mean age 64.7 years in this arm | 900 mg | 90 days | 30 |
| Repeated administration of berberine inhibits cytochromes P450 in humans 2012 · berberine capsules · Healthy Chinese male volunteers, mean age 21.6 years; no stated condition | 900 mg | 2 weeks | 18 |
| Berberine is an insulin secretagogue targeting the KCNH6 potassium channel 2021 · BBR treatment · Healthy men aged 18–45 years with normal glucose tolerance | 1 g | 1 day | 15 |
| A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis 2022 · HTD1801 500 mg BID · Patients with primary sclerosing cholangitis | 1 g | 6 weeks | 15 |
| Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes 2024 · HC + BBR · Middle-aged men with overweight or obesity and prediabetes | 1 g | 8 weeks | 9 |
| Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes 2024 · LC + BBR · Middle-aged men with overweight or obesity and prediabetes | 1 g | 8 weeks | 9 |
| Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes 2024 · BBR · Middle-aged men with overweight or obesity and prediabetes | 1 g | 8 weeks | 9 |
| Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study 2005 · Pharmacokinetic study BBR co-administration phase · Six renal-transplant recipients receiving cyclosporin A | 600 mg | 12 days | 6 |
| Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine 2008 · berberine group · Patients with type 2 diabetes and dyslipidemia | 1 g | 90 days | — |
| Effects of berberine on lipid profile in subjects with low cardiovascular risk 2013 · berberine · Caucasian subjects with low cardiovascular risk | 1 g | 26 weeks | — |
| Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects 2019 · Bbr 300 mg · Healthy Chinese men and women aged 18–50 years | 900 mg | 7 days | — |
| Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects 2019 · Bbr 300 mg plus Svt 40 mg · Healthy Chinese men and women aged 18–50 years | 900 mg | 7 days | — |
| Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects 2019 · Bbr 300 mg plus Fbt 200 mg · Healthy Chinese men and women aged 18–50 years | 900 mg | 7 days | — |
| The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial 2021 · berberine · Patients diagnosed with schizophrenia | 900 mg | 8 weeks | — |
| Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment 2012 · BBR/P/RR monotherapy · Adults with primary polygenic hypercholesterolemia who were statin-intolerant or declined statin treatment | 500 mg | 180 days | 152 |
| Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment 2012 · Supplementary BBR/P/RR in HeFH patients on stable statin treatment or statin plus ezetimibe · Adults with genotype-confirmed heterozygous familial hypercholesterolemia on stable-dose statins or statins plus ezetimibe | 500 mg | 90 days | 30 |
| Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment 2012 · Combined BBR/P/RR plus ezetimibe therapy · Adults with primary hypercholesterolemia selected for a low response to monotherapy | 500 mg | 90 days | 26 |
| Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial 2015 · Combination B · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant | 531 mg | 4 weeks | 23 |
| Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans 2022 · Quillaja extract-emulsified berberine · Healthy men and women | 800 mg | 1 day | 12 |
| Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial 2021 · B500 (berberine) · Healthy, physically active males aged 18–45 years; five participants completed the study. | 1.5 g | 2 days | 5 |
| Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial 2015 · Combination A · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant | 500 mg | 4 weeks | 23 |
| Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study 2017 · Body Lipid (BL) · Adults aged 18–75, both sexes, with mild-to-moderate hypercholesterolemia | 500 mg | 4 weeks | — |
| Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study 2017 · Armolipid Plus (AM) · Adults aged 18–75, both sexes, with mild-to-moderate hypercholesterolemia | 500 mg | 4 weeks | — |
| Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease 2015 · Group C — LSI plus BBR · Adults with NAFLD and impaired glucose regulation or type 2 diabetes of less than 1 year’s duration | 1.5 g | 16 weeks | 62 |
| [Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus] 2018 · intervention group · Adults aged approximately 55 years with type 2 diabetes mellitus | 1.2 g | 26 weeks | 57 |
| Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease 2016 · Group B—LSI plus BBR · Adults with NAFLD and impaired glucose regulation or type 2 diabetes | 1.5 g | 16 weeks | 41 |
| Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial 2024 · BBR group · Adults with metabolic dysfunction-associated fatty liver disease (MAFLD); age range and sex not specified | 1.5 g | 12 weeks | 35 |
| The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial 2025 · Group 1 (berberine group) · Adults aged 40–60 years with MAFLD, BMI 27.0–34.9 kg/m², and abdominal obesity; women were at least one year post-menopause. | 1.5 g | 12 weeks | 35 |
| Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study 2024 · Group B (BBR) · Mexican adults over 18 years of both genders with obesity (BMI >30 kg/m²), no previous T2DM diagnosis, and at least two T2DM risk factors | 1.5 g | 90 days | 25 |
| A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis 2022 · HTD1801 1000 mg BID · Patients with primary sclerosing cholangitis | 2 g | 6 weeks | 24 |
| Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial 2023 · supplemented group · Overweight adults (28 females and 21 males across both study groups) with impaired fasting blood glucose; ages not reported | 1.1 g | 60 days | 24 |
| Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial 2023 · Treatment Group · Adults aged 18–55, male or female, with prediabetes | 1.5 g | 12 weeks | 17 |
| Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial 2021 · BBR · Adults aged 30–60 years with mixed dyslipidemia | 1.5 g | 90 days | 12 |
| Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial 2021 · BBR plus bezafibrate · Adults aged 30–60 years with mixed dyslipidemia | 1.5 g | 90 days | 12 |
| Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial 2019 · Armolipid Plus (AP) · Adults aged 18–70 with metabolic syndrome and left ventricular hypertrophy; men and women | 500 mg | 24 weeks | 71 |
| Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection 2023 · berberine group · Adults living with HIV under virological suppression and with metabolic syndrome | 1.5 g | 20 weeks | 22 |
| Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans 2022 · Vitamin E TPGS-emulsified berberine · Healthy men and women | 800 mg | 1 day | 12 |
| Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study 2021 · BB group (berberine and Bifidobacterium) · Adults aged 18–70 with newly diagnosed hyperglycemia | 1 g | 16 weeks | 49 |
| Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study 2010 · nutraceutical combination (NC) · Adults with hypercholesterolemia; mean age 55 years; 26 males and 24 females were randomized across both arms | 500 mg | 10 weeks | 25 |
| Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial 2014 · Intervention (Armolipid Plus/AP) · Men and women older than 18 years with mild-moderate hypercholesterolemia and elevated LDL-c, candidates for lifestyle intervention without hypolipemic drug treatment | 500 mg | 12 weeks | 51 |
| Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study 2017 · Nutraceutical compound · Men and women aged 18–75 with hypercholesterolemia and non-HDL-C ≥160 mg/dL | 200 mg | 12 weeks | 30 |
| Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome 2011 · intervention arm · Postmenopausal women with metabolic syndrome | 200 mg | 14 weeks | 25 |
| Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial 2019 · Nutraceutical B · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded. | 500 mg | 6 weeks | 23 |
| Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial 2010 · treatment arm · Healthy postmenopausal women | 200 mg | 14 weeks | 16 |